Keyword: Philippines

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

After two refusals from Sanofi to provide a refund for the Dengvaxia program, officials in the Philippines say they are getting ready to sue.

“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” said Sanofi.

The Philippine DOH is now officially asking Sanofi to refund some $39 million for used Dengvaxia doses as well.

A Sanofi executive said the company will "shoulder the cost" of any adverse events that are scientifically linked to vaccination.

As investigations in the Philippines proceed, Sanofi Pasteur has agreed to refund the cost of unused Dengvaxia doses worth about $28 million.

Following mass immunization program halt, Dengvaxia’s marketing authorization in the Philippines has been put on hold for a year.

More than 70 mothers in the Philippines whose children were vaccinated against dengue filed a criminal complaint against government and company officials.

As Philippines lawmakers continue probing the country's now-controversial dengue immunization program, a former president has spoken up to defend it.

As questions swirl over who knew what and when in the Philippines regarding Sanofi's dengue vaccine, the company took a chance Wednesday to pause and explain its case.